Cas No.:	175481-36-4
Chemical Name:	Lacosamide
Synonyms:	LACOSAMIDE;(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide;(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide;ADD 243037;Erlosamide;Harkoseride;SPM 927;(R)-2-Acetamido-N-benzyl-3-methoxypropanamide;Lacosamide solution;Erlosamide [INN];S1253_Selleck;Vimpat;(2R)-N-benzyl-2-acetaMido-3-MethoxypropanaMide;(2R)-2-acetamido-N-benzyl-3-methoxypropanamide;ADD 234037;563KS2PQY5;Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-;(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide;(R)-2-Acetylamino-N-benzyl-3-methoxy-propionamide;harkeroside;Lacosamide [USAN:INN:BAN];ADD 2;HY-13015;Tox21_113857;LACOSAMIDE [VANDF];LACOSAMIDE (MART.);(R)-N-benzyl-2-acetamido-3-methoxypropanamide;LACOSAMIDE CV (USP-RS);CHEBI:135939;LACOSAMIDE [EP MONOGRAPH];Lacosamide 1.0 mg/ml in Acetonitrile;N03AX18;DB06218;Lacosamide- Bio-X;(R)-2-acetamido-N-benzyl-3-methoxypropionamide.;DTXSID1057666;Lacosamide;LACOSAMIDE [WHO-DD];BDBM50300204;N~2~-Acetyl-N-benzyl-O-methyl-D-serinamide;CS-0529;BL164605;Lacosamida;SPM-929;GTPL7472;(2R)-2-acetamido-3-methoxy-N-(phenylmethyl)propanamide;KS-1227;AB01559947-01;(r)-lacosamide 1;LACOSAMIDE [ORANGE BOOK];UNII-563KS2PQY5;ADD-234037;DTXCID2031455;Lacosamide (JAN/USAN/INN);175481-36-4;(R)-2-Acetylamino-N-benzyl-3-methoxypropionamide;MOTPOLY;BB 0260890;VPPJLAIAVCUEMN-GFCCVEGCSA-N;Lacosamide [USAN];LACOSAMIDE [MART.];LACOSAMIDE [USP MONOGRAPH];Vimpat (TN);ertosamide;Motpoly XR;SR-01000942286;lacosamidum;Lacosamide cv;Lacosamide Oral Solution;(R)-2-acetamido-N-benzyl-3-methoxypropionamide;LACOSAMIDE [INN];SCHEMBL35330;LACOSAMIDE (USP MONOGRAPH);LACOSAMIDE (EP MONOGRAPH);CHEMBL58323;SPM-927;(2R)-2-acetylamino-N-benzyl-3-methoxypropanamide;(R)-N-Benzyl-2-acetamido-3-methoxypropionamide;NCGC00253740-01;A3897;DEA No. 2746;AR-270/11402703;LQO;LACOSAMIDE [MI];ADD243037;(R)-2-acetamido-N-benzyl-3-methoxypropanamide;2-(Acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-;D07299;AM808141;()-(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide;ADD-243037;AC-22750;(R)-N-benzyl 2-acetamido-3-methoxypropionamide;SPM927;CAS-175481-36-4;LACOSAMIDE [EMA EPAR];SR-01000942286-1;LACOSAMIDE [USP-RS];Lacosamide racemate;Q420077;(+)-(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide;BCP02197;LACOSAMIDE [JAN];(R)-N-benzyl 2-acetamido-3-methoxypropionamide,;AKOS005146274;ViMpat;LacosaMide (1.0Mg/ML in Acetonitrile)
SMILES:	O(C([H])([H])[H])C([H])([H])[C@]([H])(C(N([H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O)N([H])C(C([H])([H])[H])=O
Formula:	C13H18N2O3
M.Wt:	250.2936
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Lacosamide is a functionalized amino acid that produces activity in the maximal electroshock seizure (MES) test, that, like some other antiepileptic drugs (AEDs), are believed to act through voltage-gated sodium channels. Lacosamide enhances the slow inactivation of voltage-gated sodium channels without affecting the fast inactivation of voltage-gated sodium channels. This inactivation prevents the channel from opening, helping end the action potential. Many antiepileptic drugs, like carbamazepine or lamotrigine, slow the recovery from inactivation and hence reduce the ability of neurons to fire action potentials.